If a patient exhibits at least two of these 11 behaviors, it may signal a problematic pattern of opioid use leading to clinically significant impairment or distress.
Clinical colleagues in psychiatry have given us a new definition, framework and context for assessment of OUD with the publication of the Diagnostics and Statistical Manual 5 (DSM-5) in 2013.1 The longstanding model and language of substance abuse and dependence have been largely replaced by a single disorder along a continuum of mild to severe. The current language used to describe a substance problem was updated to reflect changing patterns of abuse. Criteria were changed to better account for cultural and socioeconomic effects on populations.
Treatment for OUD in pregnancy must include a multifaceted, comprehensive approach as behavioral interventions, psychosocial support and medication administration have been shown to improve maternal and neonatal outcomes.2 Pharmacotherapy for treatment of OUD (referred to as medication-assisted therapy [MAT]) has been utilized in pregnancy since the 1970s.3,4 Initially this was achieved with methadone and later with buprenorphine-based products. The benefits of MAT use in pregnancy stem from avoidance of symptomatic withdrawal. When cyclic use and withdrawal from illicitly obtained opioids is controlled, patients have the opportunity to establish and maintain medical and prenatal care and to address comorbid conditions. This reduction in medical and social risks associated with substance use in pregnancy leads to improved social, obstetric, and neonatal outcomes.5
For more information: The opioid crisis: Prenatal and postnatal care
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More